| Clinical Trials |
|
The Urology Department continues to conduct Clinical Trials investigating the psycho-social consequences of diagnosis and treatment of prostate cancer.
There are plans to investigate and develop a program to facilitate coping with prostate cancer. In addition to this, the Department is participating in pharmaceutically supported trials for treatment of advanced prostate cancer and prostate cancer prevention.
Clinical Trial Coordinators
Ms Helen Crowe helen.crowe@mh.org.au
Ms Pat Bugeja pat.bugeja@mh.org.au
Ms Lidia Veca lidia.veca@mh.org.au
Ms Liz Hayes elizabeth.hayes@mh.org.au
Telephone 9342 8442
Facsimile 9342 8928
Current Clinical Drug Trials
A study of solifenacin succinate compared to oxybutynin hydrochloride and placebo in subjects with symptoms of neurogenic detrusor overactivity (known as the SONIC study)
A Phase III Randomized, Controlled, Superiority Study Evaluating the Fibrin Pad Versus Standard of Care Treatment in Controlling Severe Soft Tissue Bleeding During Abdominal, Retroperitoneal, Pelvic, and Thoracic Surgery
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer (COU-AA-302)
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisolone in Patients with Metastatic Castration-Resistant Prostate Cancer (CRPC) Who Have Failed Docetaxel-Based Chemotherapy (Protocol Number: COU-AA-301)
Comparison of THVD-201, combination of tolterodine and a muscarinic agonist vs. tolterodine alone vs. placebo in patients with overactive bladder (OAB) symptoms
An observational study of the uRNA-2 urine test for the monitoring of recurrence of urinary tract transitional cell carcinoma (TCC) (known as The uRNA - 2 monitoring study) | 
